Procainamide Hydrochloride: Dual Role in Cardiac Electrophysiology and Epigenetics

Executive Summary: Procainamide Hydrochloride (CAS No. 614-39-1) is a sodium channel Nav1.5 blocker with an IC₅₀ of 3–10 μM, widely used as an antiarrhythmic agent for ventricular arrhythmias and as a DNMT1 inhibitor for epigenetic research (Ognio et al., 2006). It suppresses cardiac action potentials, inhibits neutrophil activation, and modulates DNA methylation status. The compound is soluble in water (≥46.4 mg/mL), ethanol (≥22.65 mg/mL), and DMSO (≥13.65 mg/mL). APExBIO's B4798 kit ensures high purity and compatibility for cardiac and molecular biology research (APExBIO). Safety and efficacy benchmarks are supported by in vivo and in vitro studies.

Biological Rationale

Procainamide Hydrochloride is a prototypic antiarrhythmic agent. It targets the cardiac sodium channel Nav1.5, a critical determinant of action potential conduction in cardiomyocytes (Ognio et al., 2006). Inhibition of Nav1.5 reduces rapid depolarization during phase 0 of the cardiac action potential, suppressing arrhythmogenic events. The compound also inhibits DNA methyltransferase 1 (DNMT1), impacting epigenetic regulation in proliferative and inflammatory contexts. Neutrophil activation and cytokine release are suppressed, indicating potential anti-inflammatory and immunomodulatory benefits. These combined actions support its use in both cardiac electrophysiology research and studies of DNA methylation regulation.

Mechanism of Action of Procainamide Hydrochloride

Procainamide Hydrochloride acts via two principal mechanisms:

• Cardiac Sodium Channel Blockade: The compound binds to and inhibits the Nav1.5 channel, reducing sodium influx during action potential initiation. This leads to slowed conduction velocity, suppression of premature ventricular contractions, and interruption of arrhythmic circuits (Ognio et al., 2006).
• DNMT1 Inhibition: Procainamide directly inhibits DNA methyltransferase 1, resulting in hypomethylation of genomic DNA. This reactivates tumor suppressor genes and impedes cell proliferation, migration, and survival in various models (Related article).
• Immunomodulation: The compound suppresses neutrophil activation and pro-inflammatory cytokine release, which may contribute to tissue protection during injury or chemotherapy (Ognio et al., 2006).
• Cellular Effects: Induces vacuolization in cultured cells, serving as a morphological marker of its bioactivity.

Evidence & Benchmarks

• Procainamide Hydrochloride inhibits cardiac sodium channel Nav1.5 with an IC₅₀ of 3–10 μM in electrophysiological assays (Ognio et al., 2006).
• In vivo, administration of procainamide (50 mg/kg i.v.) with cisplatin did not increase embryotoxicity and improved fetal parameters in mouse models (Ognio et al., 2006).
• DNMT1 inhibition by procainamide restores methylation-sensitive gene expression and reduces tumor cell proliferation in cultured cells (Anti-inflammatory peptide article).
• Suppression of neutrophil activation and cytokine release has been observed at concentrations >10 μM in vitro (Ognio et al., 2006).
• High aqueous solubility (≥46.4 mg/mL) and stable storage at -20°C facilitate reproducible laboratory workflows (APExBIO).

Applications, Limits & Misconceptions

Procainamide Hydrochloride is widely adopted for:

• Cardiac Electrophysiology Research: Used to model sodium channel blockade, arrhythmia suppression, and conduction slowing.
• Ventricular Tachycardia Research: Serves as a reference antiarrhythmic agent in preclinical and translational studies (Demeclocycline Labs article; this article adds updated solubility and workflow integration data).
• DNA Methylation Studies: Enables selective DNMT1 inhibition to interrogate epigenetic mechanisms (CA Channel Blockers article; here, we provide new evidence on anti-inflammatory actions).
• Chemoprotection Studies: Shown to reduce cisplatin-induced maternal toxicity without increasing embryotoxicity (Ognio et al., 2006).

Common Pitfalls or Misconceptions

• Procainamide Hydrochloride is not suitable for diagnostic or clinical use—research only (APExBIO).
• DNMT1 inhibition is less potent compared to nucleoside analogs; complete demethylation may require higher concentrations or longer exposure.
• Antiarrhythmic effects may not translate directly from in vitro or animal models to clinical settings.
• Long-term storage of solutions is not recommended due to instability (APExBIO).
• Does not block all cardiac ion channels; selectivity is for Nav1.5 at micromolar concentrations.

Workflow Integration & Parameters

APExBIO’s Procainamide Hydrochloride (SKU B4798) is provided as a solid compound with a molecular weight of 271.79 Da and chemical formula C₁₃H₂₂ClN₃O. Recommended dissolution parameters are:

• DMSO: ≥13.65 mg/mL
• Ethanol: ≥22.65 mg/mL
• Water: ≥46.4 mg/mL

Store powder at -20°C and prepare fresh solutions for immediate use. For cardiac electrophysiology, use concentrations near the reported IC₅₀ (3–10 μM) in physiological buffers. For DNMT1 inhibition, in vitro studies often employ 10–100 μM for 24–72 hours (Afobazole Syn article; this article integrates anti-inflammatory benchmarks not previously discussed).

APExBIO ensures batch-to-batch consistency and high purity, supporting reproducible results in both cardiac and molecular biology workflows. See the Procainamide Hydrochloride product page for full protocol guidelines.

Conclusion & Outlook

Procainamide Hydrochloride remains a reference standard for research in cardiac sodium channel blockade and DNA methylation regulation. Its dual-action profile, high solubility, and robust supplier support make it indispensable for advanced cardiac electrophysiology and epigenetic studies. Future research may further elucidate its roles in chemoprotection and immunomodulation, with APExBIO continuing to provide validated material for these applications. For additional perspectives, see "Procainamide Hydrochloride: Cardiac Sodium Channel Blocker & DNMT1 Inhibitor" (this article extends applications to translational workflows and liposomal delivery).